Nanos Standard & Poor's 500(NANOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NANOS Nanos Standard & Poor's 500

Not Yet Opened 11-25 16:00:00 EST

598.74

+1.81

+0.30%

High602.08	Low596.39	Vol0.00
Open599.23	D1 Closing596.93	Amplitude0.95%
Mkt Cap0.00	Tradable Cap0.00	Total Shares0.00
T/O--	T/O Rate--	Tradable Shares0.00
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"NANOS","market":"US","secType":"STK","nameCN":"Nanos Standard & Poor's 500","latestPrice":598.74,"timestamp":1732568400000,"preClose":596.93,"halted":0,"volume":0,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":1.81,"latestTime":"11-25 16:00:00 EST","open":599.23,"high":602.08,"low":596.39,"amount":0,"amplitude":0.009532,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1732611600000},"marketStatusCode":0,"adr":0,"adjPreClose":596.93,"symbolType":"index","impliedVol":0,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/NANOS/tweets","defaultTab":"tweets","newsList":[{"id":"2418837220","title":"GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2418837220","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2418837220?lang=en_us&edition=fundamental","pubTime":"2024-03-12 14:30","pubTimestamp":1710225000,"startTime":"0","endTime":"0","summary":"Rate of visual improvement  among patients treated with LUMEVOQ gene therapy is greater than that of idebenone-treated patients and untreated patients. First set of meta-analyses to compare visual outcomes in Leber Hereditary Optic Neuropathy  patients with the ND4 mutation only. Figure 1. Visual Recovery  Among ND4 LHON Patients – Results from Three New Meta-Analyses3,4. The meta-analyses depict a gradient of efficacy of visual recovery with LUMEVOQ intravitreal gene therapy resulting in greater recovery rates than that of idebenone treatment, and both greater than that in the natural history of the disease. This gradient of recovery, based on the CRR measure of visual improvement, is observed at both eye level and patient level . There is no overlap in confidence intervals when LUMEVOQ is compared to idebenone and to natural history, indicating a positive difference in visual outcomes.Based on the pre-defined statistical analysis plan, the three meta-analyses were performed on three ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22915774","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4561","NANOS","AAC"],"gpt_icon":0},{"id":"2417239888","title":"GenSight Biologics Announces Update on Real-World Data from Early Access Programs of LUMEVOQ® Gene Therapy at NANOS 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2417239888","media":"StreetInsider","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2417239888?lang=en_us&edition=fundamental","pubTime":"2024-03-06 14:37","pubTimestamp":1709707020,"startTime":"0","endTime":"0","summary":"Clinically meaningful improvement in visual acuity confirmed in a real-world setting: on-chart mean visual acuity at 9 months after injection, compared to off-chart mean at baseline. Eyes of bilaterally treated patients improve more than those of unilaterally treated patients: +23 ETDRS letters vs. +18 ETDRS letters, with a higher responder rate , with a similar and favorable safety profile. One year after treatment, eyes of bilaterally injected patients experienced an average gain from nadir1 in best-corrected visual acuity  equal to +23 ETDRS letters, greater than the 18-letter average gain among patients with only one eye injected. In both groups, the clinical improvement exceeded the conventional definition of clinical meaningfulness, in which a 15-letter gain is considered meaningful. The safety profile of the gene therapy continues to be favorable and comparable between bilaterally treated patients and unilaterally treated patients.One year after treatment, responder analyses sho","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22890472","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_streetinsider","symbols":["BK4561","NANOS","AAC"],"gpt_icon":0},{"id":"2416169738","title":"GenSight Biologics Announces LUMEVOQ® Scientific Updates at NANOS 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2416169738","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2416169738?lang=en_us&edition=fundamental","pubTime":"2024-03-04 14:30","pubTimestamp":1709533800,"startTime":"0","endTime":"0","summary":"GenSight Biologics , a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that new scientific data and analyses on the gene therapy LUMEVOQ will be presented at the 50th Annual Meeting of the North American Neuro-Ophthalmology Society  in Honolulu, Hawaii .Leading Leber Hereditary Optic Neuropathy  Key Opinion Leaders will provide updates on evidence related to the contralateral effect, on real-world experience with LUMEVOQ, and on the comparison between LHON natural history, idebenone and LUMEVOQ.Poster presentation: \"Unilateral injection of lenadogene nolparvovec gene therapy induces successful transfection of retinal ganglion cells in both eyes\". Presenter: Alfredo A. Sadun, MD, PhD, Doheny Eye Centers-UCLA, Pasadena, California, USA","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Hu7BP_7BDLlvdRlegPgbRg--~B/aD0yMDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/13e85e6c1fa475bf61979c8bf84043e4","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Hu7BP_7BDLlvdRlegPgbRg--~B/aD0yMDQ7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/13e85e6c1fa475bf61979c8bf84043e4"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/gensight-biologics-announces-lumevoq-scientific-063000692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4533","GS","BK4127","BK4552","LU1668664300.SGD","GSGTF","LU0106831901.USD","BK4550","IE0034235188.USD","BK4585","BK4139","BK4504","NANOS","BK4588","IE00BSNM7G36.USD"],"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0159},{"period":"1month","weight":0.0319},{"period":"3month","weight":0.0641},{"period":"6month","weight":0.1358},{"period":"1year","weight":0.3124},{"period":"ytd","weight":0.2571}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"exchange":"CBOE","name":"Nanos Standard & Poor's 500","nameEN":"Nanos Standard & Poor's 500"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nanos Standard & Poor's 500(NANOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nanos Standard & Poor's 500(NANOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nanos Standard & Poor's 500,NANOS,Nanos Standard & Poor's 500股票,Nanos Standard & Poor's 500股票老虎,Nanos Standard & Poor's 500股票老虎国际,Nanos Standard & Poor's 500行情,Nanos Standard & Poor's 500股票行情,Nanos Standard & Poor's 500股价,Nanos Standard & Poor's 500股市,Nanos Standard & Poor's 500股票价格,Nanos Standard & Poor's 500股票交易,Nanos Standard & Poor's 500股票购买,Nanos Standard & Poor's 500股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nanos Standard & Poor's 500(NANOS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nanos Standard & Poor's 500(NANOS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction